化合物A联合 化合物 B对人肝癌HepG2细胞作用机制研究论文.docVIP

. PAGE 16 .. . .. 本 科 毕 业 论 文 论文题目： 化合物A联合 化合物 B对人肝癌HepG2细胞作用机制研究 . . 目 录 中文摘要······································································1英文摘要······································································2 第1章 绪论··································································3 1.1细胞凋亡·····························································3 1.2立题依据·····························································5 第2章 实验部分······························································6 2.1实验材料·····························································6 2.2实验方法·····························································7 2.3实验结果····························································12 第3章 结论与讨论···························································17 3.1结论································································17 3.2讨论································································18 参考文献·····································································21致谢·········································································23 . 摘 要 原发性肝癌是世界常见的恶性肿瘤之一，也是我国的高发恶性肿瘤，由于不易被早期诊断，进展迅速，术后容易复发、转移，因此预后较差。目前肝癌仍以外科手术为公认首选和主要的治疗手段，但由于很多肝癌患者确诊时已是中晚期，失去了手术治疗的机会并于诊断后1年内死亡，手术切除率30%，术后总体5年生存率仅30%~40%。对于可手术的肝癌患者，术后复发、转移是影响治疗效果及预后的主要因素，对于不能手术的中晚期肝癌患者尚缺乏有效的治疗方法。传统的化疗、放疗对肝癌疗效欠佳，目前仍缺乏行之有效的化学预防和治疗靶位[1]。因而本课题是对化合物 A联合化合物 B对人肝癌HepG2细胞作用机制研究。 本实验首先用MTT法分别测得不同浓度的A和B单独处理HepG2细胞及不同浓度的A和B联合用药处理HepG2细胞死亡的影响。结果表明不同浓度的A和B单独处理HepG2细胞，增值抑制程度表现为时间剂量依赖效应，并且在A 6μmol/L联合B 100μmol/L协同作用最为显著。流式细胞仪检测细胞凋亡率显示，联合用药组凋亡率升高更为明显。Western Blot法检测蛋白显示，促凋亡相关蛋白Bax、FADD增加，抗凋亡蛋白Bcl-2 表达减少。 关键词 联合用药，细胞凋亡，作用机制 . Abstract Hepatocellular carcinoma (HCC) is the most common cancer in the world and an increased malignant illness in our country. Because of its aggressive biological behavior, rapidly progresses and delayed diagnosis, this malignancy has a grim prognosis even following surgical resection and has high disease-recurrence. Surgery is the first and most com